

Date: 30th May, 2018

To,

Bombay Stock Exchange Limited

Phiroze Jeejeebhoy Towers

Dalal Street,

Mumbai – 400 001

Sub: Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements), 2015 regarding Audit Report with unmodified opinion

Script Code: 540359

Dear Sir,

We hereby declare that the statutory auditor of our company B.A. SHAH & ASSOCIATES, Chartered Accountant (Reg.No.109493W) has issued the Audit Report with unmodified opinion in respect of Audited Financial Results for the financial year ended on 31.03.2018 under SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.

You are requested to take note of the above.

Yours faithfully,

For PARMAX PHARMA LIMITED


XR GOSOM

ALKESH GOSALIA

Director

DIN: 01130615

Regd. Off. & Factory: Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 Fax: +91-2827-270536 e-mail: info@parmaxpharma.com CIN: L24231GJ1994PLC023504





					70000 10000	(in Rs.	
Sr. No.	Particulars	Quarter Ended			Year Ended		
140,		31.03.2018	31.12.2017	31.03.2017	31.03.2018	31.03.2017	
	(Refer Notes Below)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	
l. II.	Revenue from operations Other income	31592065 181290	25785127 45882	150000	119015986 472423	600000	
111.	Total Income (I+II)	31773355	25831009	150000	119488409	600000	
IV.	Expenses						
	(a) Cost of materials consumed (b) Purchase of stock-in-trade	13289710 0	16963439 0	0	70645775 0		
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-3758815	-7268692	0	-12830395		
	(d) Employee benefits expense (e) Finance Costs	2706351 56933	6574520 91962	0	21313498 335776	(	
	(f) Depreciation and amortisation expense (g) Other expenses	3103261	2615600	o	10929861		
	\$26,00 = 12,000 P) 1 1 (10 to 2 (20 to 0)	13536115	6485151	115444	29077352	548787	
	Total expenses (IV)	28933555	25461980	115444	119471867	548787	
V	Profit/(Loss) from operations before exceptional items and tax (I-IV)	2839800	369029	34556	16542	51213	
VI	Exceptional Items	0	0	0	0	51213	
VII	Profit/ (Loss) before tax (V-VI)	2839800	369029	34556	16542	51213	
VIII	Tax expense:	0	0	0	0	130000	
	(1) Current tax (2) Deferred tax					130000	
X	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	2839800	369029	34556	16542	-78787	
	Profit/(loss) from discontinued operations  Tax expense of discontined operations					-	
KII	Profit/(loss) from Discontined operations (after tax) (X-XI)						
KIII	Profit (Loss) for the period (IX+XII)	2839800	369029	34556	16542	-78787	
(IV	Other Comprehensive Income A. (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss				10012	1000	
	B. (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss	0	0	0	0		
cv	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)	2839800	369029	34556	16542	-78787	
(VI	Paid-up equity share capital (Face Value Rs 10)	37413000	37413000		20100000000	201222	
	Earnings per share (for continuing operation & discontinuing operation) (of Rs. 10/- each ): (a) Basic (b) Diluted	0.76	0.10	37413000	37413000	-0.02	

## Notes:


- 1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 30th May, 2018 and the same have been audited by the Stautory Auditors in compliance with Regulation 33 of SEBI (LODR) Reg., 2015. The Statuory Auditors have issued an unqualified audit report.
- 2. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
- 3. Statement of Audited Financial Results of the company for the quarter and year ended 31st March, 2018, in the prescribed format under Schedule III of Companies Act, 2013
- 4. The figures for the previous period have been regrouped wherever necessary.
- 5. The company has adopted Indian Accounting Standards (Ind-AS) from 1st, April, 2017 and these financial results have been prepared in accordance with the Ind-AS as specified under section 133 of Companies Act, 2013.
- 6. The figures stated above for quarter and year ended 31st March, 2017 are as per Ind AS and in complete reconciliation with previously applicable GAAP. No difference has been observed between the same. For reference, reconciliation table is provided below:

	tion of Net Profit as previously reported under Indian GAAP to Ind-AS is as under:					
Particulars	Quarter ended 31.03.2017	Year ended 31.03.2017				
Net Profit/Loss as per previous GAAP (IND GAAP)	34556	-78787				
Adjustments	Nil	Nil				
Net Profit/Loss as per IND A\$	34556	-78787				

FOR, PARMAX PHARMA LIMITED

Place: Hadamtala (Rajkot) Date: 30.05.2018 Alkesh Gosalia

Regd. Off. & Factory: Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311,





## Statement of Assets and Liabilities

No.	Particulars	As at 31.03.2018 (Audited)	(Audite	1.03.2017 ed)
	Assets		-	
	Non-current assets	58626140		27248020
	(a) Property, Plant and Equipment	0		0
	(b) Capital work-in-progress	0		. 0
	(c) Investment Property	0	_	0
	(d) Goodwill		-	0
	(e) Other Intangible assets	0	-	0
	(f) Intangible assets under development		-	0
	(g) Biological Assets other than bearer plants		-	0
	(h) Financial Assets	6000		6000
	(i) Investments			0
	(ii) Trade receivables	78069	9	750899
	(iii) Loans		0	0
	(i) Deferred tax assets (net)	1549246	6	11974466
	(j) Other non-current assets	-		39979385
	Total Non-Current Asset	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
	Current assets	3217822	6	17635195
	(a) Inventories		0	0
	(b) Financial Assets		0	0
	(i) Investments	1972005	-	1204682
	(ii) Trade receivables	957686		1711258
	(iii) Cash and cash equivalents		0	0
	(iv) Bank balances other than(iii) above	296440	51	16603951
	(v) Loans	1 200,100	0	0
	(vi) Others (to be specified)		0	C
	(c) Current Tax Assets (Net)		0	(
	(d) Other current assets Tatal Current Asse	ts 911192	06	37155086
	Total Asse	The second secon	10	7713447
	EQUITY AND LIABILITIES			- 4
1.			-	
1	Equity (a) Equity Share capital	445115	500	4451150
-		1065	775	104923
_	(b) Other Equity	45577	275	4556073
_	Total Equity			
2	Non-current liabilities			
i.	(a) Financial Liabilities		0	
-	- Itali	21624	233	1024917
	(i) Borrowings (ii) Trade payables		0	
	(iii)Other financial liabilities (other than those specifie	ed .		
	in item (b), to be specified		0	
	(b) Provisions	-	0	
	(c) Deferred tax liabilities (Net)		0	
	(d) Other non-current liabilities	ities 2162	-	102491
	Total of Non-Current Liabil	ities 2102	+233	202.00
ii.	Current liabilities		0	
	(a) Financial Liabilities		0	
	(i) Borrowings	0640	4318	208955
	(ii) Trade payables		4510	20000
	(iii) Other financial liabilities (other than those specifinitem (c)		0	
-	(b) Other current liabilities		5131	34
-	(c) Provisions	223	33551	395
-	(d) Current Tax Liabilities (Net)		0	
-	Total of Current Liab	ilities 988	23000	21324
	Total Equity and Liabilities	1660	24510	77134

FOR PARMAX PHARMA LIMITED

Place: Hadamtala (Rajkot) Date: 30.05.2018 Alkesh Gosalia Director

Regd. Off. & Factory: Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 Fax: +91-2827-270536 e-mail: info@parmaxpharma.com CIN: L24231GJ1994PLC023504

## BHARAT A. SHAH

B.Com. F.C.A. (DISA)

## **B. A. SHAH ASSOCIATES**

**Chartered Accountants** 

209 Sapphire, 2<sup>nd</sup> Floor, 21/25 - B ,New Jagnath Plot, Rajkot. - 360 001. Ph.: 0281 - 2468261

Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of
Parmax Pharma Ltd

We have audited the quarterly financial results of **Parmax Pharma Limited** for the quarter ended 31<sup>st</sup> March 2018 and the year to date results for the period 01.04.2017 To 31.03.2018, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25 / Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended 31<sup>st</sup> March 2018 as well as the year to date results for the period from 01.04.2017 to 31.03.2018.

Place: RAJKOT Date: 30.05.2018 RAJKOT SHAPER ACCOUNTS

For

B.A. SHAH ASSOCIATES Chartered Accountant FRN::109493W

Bharat A Shah

BHARAT A. SHAH Proprietor

M. No.: 034222